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ABSTRACT: Atrial natriuretic peptide (ANP) is released from the 
heart and induces the elicitation of guanylate cyclase enzyme 
activity. It has vasodilatory and natriuretic properties. In this study 
we elucidated the determination of ANP deoxyribonucleotide (DNA) 
and its truncated peptide ANP (4-28) by agarose gel electrophoresis. 
The techniques combined the use of polymerase chain reaction and 
gel electrophoresis for simple estimation of DNA content from 
biological samples. 
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Summary of the paper 
Atrial natriuretic peptide (ANP) is a 28-amino acid (AA) peptide that 
consists of a 17-AA ring formed by a disulfide bond together with a 
6-AA N-terminus and a 5-AA C-terminus (1). Studies in animal 
models of altered ANP production or receptor function as well as 
studies in humans with ANP infusion have demonstrated that ANP 
plays an important role in integrated cardiorenal function; ANP 
possesses natriuretic, vasodilatory, lusitropic, renal enhancing, and 
renin-angiotensin-aldosterone system (RAAS) inhibiting properties 
through activation of the natriuretic peptide receptor A (NPR-A) and 
generation of the second messenger 3',5'-cyclic guanosine 
monophosphate (cGMP) (2–7). By activating NPR-A, ANP also is 
antihypertrophic and antifibrotic, and genetic deletion of either the 
ANP gene (Nppa) or NPR-A results in hypertension, cardiac 
hypertrophy, and fibrosis (8).  
The inhibition of specific signaling pathways has represented a 
classical means by which to define the function of such pathways. 
Gene disruption is one method by which to interrupt signaling 
pathways, and this has disrupted the genes for ANP, B-type 
natriuretic peptide (BNP), or GC-A . Disruption of the GC-A gene 
results in mice that display a salt-resistant elevation of blood 
pressure, and cardiac fibrosis and hypertrophy (9). The cardiac 
hypertrophy is greater than that seen in other mouse models of 
hypertension, suggesting that GC-A could be directly involved in the 
regulation of myocyte size. It has been shown, in fact, that ANP 
inhibits cardiomyocyte hypertrophy under in vitro culture conditions 
(10). ANP gene is expressed in the major organs of the body i.e 
heart, kidney, brain and testis. Keeping these important aspects in 
mind regarding the ANP gene, we  estimated the content of ANP 
cDNA extracted from the rat pituitary and its synthetic 
oligonucleotide ANP DNA (4-28)  (11) by agarose gel 
electrophoresis. The results of our study as depicted in the Figure-1 
show that the yield of ANP DNA was 0.14ng and that of the 
oligonucleotide was 0.11 ng. This study thus highlights the 
importance of PCR and gel electrophoresis in the molecular biology 
studies on this important peptide. 
 
RT-PCR and Gel Electrophoresis 
ANP cDNA for hybridization was obtained by the purification and 
sequence of RT-PCR product of rat pituitary gland. A truncated ANP 
(4-28) DNA was also run alongside for comparison. 800 mg of  
agarose was added to 10xTAE solution. It was stirred for some time. 
The volume was made to 100 ml and agarose was dissolved by 
heating in microwave. After pouring 50 ml in to the tank a suitable 
comb was fixed. The gel was allowed to solidify for 20 minutes. 4 
and 8 microliter of  ANP  DNA sample in TE buffer was added to 
each well and the gel run for 90 minutes. It was stained with 
ethidium bromide and observed on a transilluminator. The yield of 
DNA estimated was approximately 0.14 ng for ANP cDNA  and  0.11 
ng for ANP (4-28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 shows the agarose gel electrophoresis done for Atrial natriuretic peptide DNA 
and seen under a densitometric transilluminator. Lane 1- ANP 8 μl, Lane 2-ANP 4 μl, 
Lane 3-ANP (4-28)  8 μl, Lane 4-ANP (4-28) 4 μl, Lane 5- Standard DNA ladder 
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